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Abstract
Diversity and complexity of MDM2 mechanisms govern its principal function as the cellular antagonist of the p53 tumor
suppressor. Structural and biophysical studies have demonstrated that MDM2 binding could be regulated by the dynamics
of a pseudo-substrate lid motif. However, these experiments and subsequent computational studies have produced
conflicting mechanistic models of MDM2 function and dynamics. We propose a unifying conformational selection model
that can reconcile experimental findings and reveal a fundamental role of the lid as a dynamic regulator of MDM2-mediated
binding. In this work, structure, dynamics and energetics of apo-MDM2 are studied as a function of posttranslational
modifications and length of the lid. We found that the dynamic equilibrium between ‘‘closed’’ and ‘‘semi-closed’’ lid forms
may be a fundamental characteristic of MDM2 regulatory interactions, which can be modulated by phosphorylation,
phosphomimetic mutation as well as by the lid size. Our results revealed that these factors may regulate p53-MDM2 binding
by fine-tuning the thermodynamic equilibrium between preexisting conformational states of apo-MDM2. In agreement with
NMR studies, the effect of phosphorylation on MDM2 interactions was more pronounced with the truncated lid variant that
favored the thermodynamically dominant closed form. The phosphomimetic mutation S17D may alter the lid dynamics by
shifting the thermodynamic equilibrium towards the ensemble of ‘‘semi-closed’’ conformations. The dominant ‘‘semiclosed’’ lid form and weakened dependence on the phosphorylation seen in simulations with the complete lid can provide
a rationale for binding of small p53-based mimetics and inhibitors without a direct competition with the lid dynamics. The
results suggested that a conformational selection model of preexisting MDM2 states may provide a robust theoretical
framework for understanding MDM2 dynamics. Probing biological functions and mechanisms of MDM2 regulation would
require further integration of computational and experimental studies and may help to guide drug design of novel anticancer therapeutics.
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N-terminal MDM2 domain is followed by the nuclear localization
signal (NLS) and nuclear export signal (NES). Acidic domain
occupies the central region, the zinc finger (ZF) domain and the
RING finger (RF) domains are at the C-terminus [11]. Genotoxic
stress and DNA damage [26–28] can cause multiple posttranslational modifications, which are spread across different
domains in both p53 and MDM2 [29–38], and allow p53 to
escape MDM2 inhibition and degradation. Although phosphorylation of the conserved residues S15 and S20 at the amino
terminus of p53 could decrease association with MDM2 [39,40],
this may not be a universal requirement for stabilization of p53
[41]. The phosphorylation sites T18 and S20 at the p53-MDM2
interface could also modulate binding to MDM2, thus upregulating p53 levels in stressed cells [42]. However, biochemical
experiments have suggested that phosphorylation of p53 sites
alone may not be sufficient to disrupt the p53-MDM2 interactions
and synergistic coupling of p53 and MDM2 phosphorylatable sites
may be required for regulation of p53 activity [43,44]. Among
functionally important phosphorylation sites at the N-terminal

Introduction
The p53 tumor suppressor is known as ‘‘The Guardian of the
Genome’’ [1] and plays a fundamental role in maintaining the
integrity of the genome by inducing either cell cycle arrest or
apoptosis following cellular stress signals [2,3]. In normal cells the
level of p53 is tightly regulated and maintained at a low level by
the murine double minute (MDM2) oncoprotein, which is a p53specific E3 ubiquitin ligase [4–6]. MDM2 recognizes the Nterminal trans-activation domain of the p53 tumor suppressor and
is responsible for inactivation of p53 transcription and targeting
p53 for ubiquitin-mediated degradation [7–9]. MDM2 can inhibit
p53 activity by nucleo-cytoplasmic shuttling [10,11] or by binding
of its N-terminal domain to the trans-activation domain of p53
[12,13]. Overexpression of the MDM2 oncogene is common in
a variety of malignant human tumors and contributes to
inactivation of p53 [14–25]. MDM2 consists of several conserved
domains including the N-terminal domain that binds the a-helix
from the N- terminal transactivation domain of p53 [10–12]. The
PLoS ONE | www.plosone.org
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MDM2 domain is the S17 residue that can be phosphorylated by
DNA-dependent protein kinase in vitro [26]. The MDM2 phosphorylation sites are located not only at the N-terminal domain,
but also within the central domain, and near the carboxyl terminal
of the RING domain [29–38]. Following DNA damage,
phosphorylation of MDM2 sites could lead to the concomitant
changes in the protein function and stabilization of p53. To
protect p53, several signaling pathways induced by genotoxic stress
could alter the ability of MDM2 to neutralize p53 through
inhibition of the MDM2-mediated ubiquitination of p53 [29–38].
Structural basis of the MDM2-mediated p53 regulation was first
addressed based on the crystal structure of the N-terminal domain
of MDM2 bound to p53, revealing a deep hydrophobic cleft in
MDM2 to which the p53 peptide binds as an amphipathic a-helix
[45]. This study has supported the hypothesis that MDM2 can
inactivate the tumor suppressor by shielding the transactivation
domain of p53 from transcriptional machinery [45–48]. The
functional effects of p53 phosphorylation sites and peptide length
on p53-MDM2 regulation, initially addressed in a series of early
biochemical investigations [49–51], were further detailed by using
fluorescence anisotropy competition assay [52]. Although posttranslational modifications of Ser-15 and Ser-20 did not affect p53
binding to MDM2, phosphorylation of Thr-18 resulted in ,20fold binding reduction in binding, suggesting a plausible regulatory
scenario for disruption of p53-MDM2 binding. In addition, this
study has evidenced the tighter binding of a smaller peptide, p53
(18226) (Kd ,70 nM), where the additional truncation to p53
(19226) resulted in a 10-fold reduction in affinity [52]. Structurefunctional studies of MDM2 binding with p53-based peptides have
revealed significant variations in binding affinities depending on
the peptide length that can be accompanied by local and global
conformational changes in the MDM2 receptor [53,54]. These
studies have for the first time demonstrated that ligand-based
modulation of the receptor dynamics is an important organizing
principle of MDM2 function. NMR studies of the p53-derived
peptides binding with MDM2 have confirmed the important role
of Thr-18 by showing that the p53-truncated peptide (17–26) can
increase binding affinity by 13-fold, while the deletion of Thr-18 in
a shorter p53 peptide variant (19–26) completely abolished
binding [53]. This NMR study has also suggested that peptide
binding may elicit global conformational changes of MDM2,
spreading beyond local adjustments in the binding cleft [53].
Subsequent NMR spectroscopy study has confirmed that peptideinduced structural changes in MDM2 and binding affinities of
p53-derived peptides can depend on the peptide length [54].
Indeed, the isothermal titration calorimetry experiments have
demonstrated a significant improvement in MDM2 biding
between p53 (15–29) (Kd ,500 nM) and p53 (17–26) (Kd
,50 nM), reflecting the key role of enthalpy-entropy compensation in driving binding of p53-MDM2 complexes [54]. Overall,
the enhanced binding of smaller p53-based peptides, that include
Thr-18 and terminate at Leu-26, emerged as important evidence
guiding subsequent structure-functional studies of p53-MDM2
regulation and design of p53-based peptidomimetics.
The pioneering NMR study of apo-MDM2 (residues 16–125)
has discovered that the stretch of the N-terminal MDM2 residues
(residues 16–24) can form a flexible lid competing for the p53
binding site on MDM2 via a pseudo-substrate mechanism [55].
This has led to the initial conjecture of p53 regulation by
posttranslational MDM2 modifications. According to this model,
under normal conditions the lid would weakly interact with the
binding cleft and can be readily displaced by p53, whereas
phosphorylation of the S17 lid residue may induce a stable lid
conformation, ‘‘closing’’ over the p53 binding cleft and thus
PLoS ONE | www.plosone.org

inhibiting the p53-MDM2 interactions [55]. This study has
proposed that rapid in-vivo phosphorylation of the ‘‘structural
neighbors’’ p53-T18, p53-S20 and MDM2-S17 may potentially
induce the close proximity of the phosphate groups on these
residues, thus leading to the eventual abrogation of the p53MDM2 interactions and activation of p53 [55]. The complete Nterminal lid construct (residues 1–24) was not resolved in the
crystal structure of the p53-MDM2 complex [45], neither it was
well-defined in the NMR ensemble of apo-MDM2 structures [56].
Nevertheless, both NMR investigations [55,56] have consistently
observed a partial ordering of the lid motif 18-QIPASEQ-24 that
can form meta-stable intramolecular interactions in the binding
site. According to the proposed hypothesis, the closed form of the
MDM2 lid may be compatible with the smaller p53-based peptide
(17–26), thus explaining the enhanced binding affinity of p53
analogues terminating at Leu-26 [56]. Multidimensional solution
NMR studies of the N-terminal domain of human MDM2
(residues 17–125) have provided the first comprehensive analysis of
the protein dynamics in the apo-MDM2 state, the p53-bound
state, and in the complex with the nutlin-3 inhibitor [57]. This
study has shown that the lid can predominantly exist in the
‘‘closed’’ form that can effectively shield MDM2 from binding of
large peptides, yet the lid can be displaced by the p53(17–29)
peptide. Functional dynamics of the MDM2 lid has revealed a slow
exchange (.10-ms time scale) between a dominant ‘‘closed’’ form
and a minor disordered form, corresponding to the p53-bound
MDM2 state. It was also discovered that high-affinity p53-based
peptides terminating at Leu-26 and small molecule inhibitors, such
as nutlin-3, can be structurally compatible with the closed lid form
[57]. The crystal structures [58,59] and NMR structures [60] of
the MDM2 complexes with active cis-imidazoline analogs (also
known as nutlins) have unveiled that these inhibitors can utilize the
imidazole ring as a scaffold to mimic the p53-MDM2 interactions
by projecting its three hydrophobic groups into the respective
hydrophobic pockets of the MDM2 binding cleft. However, none
of these early experiments has included the lid motif in the
structure determination, and thus the specific regulatory role of the
MDM2 lid in accommodating ligand binding could not be initially
tested.
The complexity of MDM2-mediated regulatory mechanisms
and challenges associated with the rationalization of posttranslational modification effects was evidenced from conflicting results
obtained in NMR [55,57] and enzymological studies [61,62].
NMR studies have suggested that phosphorylation at S17 and
phosphomimetic mutation S17D can induce a ‘‘closed’’ form of
the lid, thus shielding the MDM2 binding cleft from p53 and
inhibiting the p53-MDM2 complex formation [55,57]. Recent
biochemical studies challenged this mechanism by offering
a contrasting mechanistic hypothesis of the MDM2-mediated
regulation [61,62]. According to this alternative model, phosphorylation and mutations at S17 would alter the lid dynamics and
result in the opening of the hydrophobic cleft, thus promoting
formation of the p53-MDM2 complex [61,62]. The supporting
evidence was based on biochemical studies of MDM2 mutants,
where the phosphomimetic mutation S17D was shown to increase
the stability of the p53-binding domain of MDM2 and facilitate
MDM2-mediated ubiquitination of p53 [61]. It was also shown
that the phosphomimetic lid could increase the thermostability of
the MDM2 protein in the presence of nutlins, p53-mimetic
peptides and other small molecule inhibitors [62]. Mutagenesis
experiments from these studies have revealed that R97S and K98P
mutants do not structurally perturb the MDM2 domain, yet the
enhanced binding of S17D to p53 can be disrupted in the S17D/
R97S/K98P triple mutant. Based on these indications, it was
2
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suggested that chemical modifications at S17 may induce opening
of the binding cleft by promoting migration of the lid from the
binding site and the formation of stabilizing interactions with the
surface residues R97 and K98 [61,62]. However, this alternative
model could not reconcile the contradictory findings where the
phosphomimetic lid should enhance the thermostability of MDM2
in the presence of p53-mimetic peptides (according to the
enzymological experiments [61,62], yet ligand binding is thermodynamically favored by the ‘‘closed’’ lid form of the MDM2
receptor (according to NMR [55,57]). The latest chapter in the
ongoing debates about the role of MDM2 phosphorylation in p53
activation was presented in an illuminating comparative analysis of
the p53-binding domain MDM2 (12109), Ser17-phosphorylated
analogue pS17 and S17D [63]. Structure and binding thermodynamics of these complete MDM2 variants were probed by a panel
of p53-derived peptide ligands using a combination of complementary experimental approaches, including surface plasmon
resonance, fluorescence polarization, NMR and CD spectroscopic
techniques [63]. This extensive biophysical characterization of
MDM2 proteins has for the first time demonstrated that the
complete N-terminal lid construct (residues 1224) can adopt
a partially structured, closed conformation in apo-MDM2 that can
weaken binding of p53-derived peptides in a size-dependent
manner. The results of this comprehensive study were largely
consistent with the earlier NMR studies [55,57] in supporting the
‘‘closed’’ model of the lid occluding the p53-binding site on
MDM2. Although NMR and CD analyses have confirmed the
presence of stabilizing intramolecular interactions mediated by
pS17 and S17D, these energetic effects were found to be transient
in nature and rather weak [63]. The central and somewhat
surprising finding of this study suggested that although phosphorylation at S17 may be functionally important to stabilize the closed
form of the lid, binding thermodynamics of p53-based peptides
can be largely independent on the phosphorylation state of the lid
at structural and functional levels [63]. These studies have thus
highlighted that the mechanism of lid-induced regulation of p53
binding may be modulated not only by the phosphorylation state,
but also by the length of the lid construct. Indeed, phosphorylation
of the truncated lid (residues 16–24) has resulted in a significant
functional effect on p53 binding seen in NMR studies [55,57] as
opposed to a considerably weaker effect observed in biophysical
studies with the complete lid (residues 1–24) [63]. The crystallographic and NMR studies have similarly offered conflicting
observations regarding ligand-induced conformational changes in
MDM2. The solution structure of apo-MDM2 (residues 2–118)
[56] has suggested that considerable conformational changes may
accompany p53 binding, thus leading to a more open and
expanded MDM2 structure in complexes with small molecules
and peptides. However, the recent NMR studies have convincingly demonstrated that the overall structure and dynamics of apoMDM2 and the peptide-bound MDM2 complexes is similar and
conformational changes modulated by ligand binding may be
primarily localized in the MDM2 lid region and in the portions of
the binding cleft [55,57]. NMR-based investigation of MDM2
phosphorylation effects on p53 activation has also demonstrated
that posttranslational modifications do not induce significant
conformational changes in the apo protein [63]. Furthermore, the
crystal structures of the MDM2 complexes with peptidomimetics
[64–75] and small molecule inhibitors [58–60,76–80] appeared to
be quite similar, suggesting that ligand binding would not
necessarily elicit global conformational changes of the MDM2
receptor.
Computational studies of p53-MDM2 binding were pioneered
by late Peter Kollman and coworkers when they introduced
PLoS ONE | www.plosone.org

a computational alanine scanning approach to evaluate contributions of the p53 residues to the binding free energy [81]. This
approach has been further developed to examine the p53-MDM2
interactions and evaluate the role of key residues in the human
p53-MDM2 complex for computational design of b-peptide p53mimetics [82]. Pharmacophore-based computational modeling
was successfully applied to design libraries of p53 mimics [83].
Computational design of p53-derived peptides has proposed that
peptide extensions may enhance binding affinities by modulating
the interactions beyond the binding cleft [84]. Molecular dynamics
(MD) simulations have elucidated conformational changes in the
p53-binding cleft suggesting that a wider and more stable topology
of the binding cleft may be induced in the MDM2 complexes,
while apo-MDM2 could favor a narrower and more flexible
binding site [85,86]. Computer simulations of the p53 transactivation domain have shown that phosphorylation at T18 and S20
residues would not disrupt the helical structure of p53, but could
rather reduce the p53-MDM2 binding affinities [87]. Subsequent
studies have shown that p53 binding to MDM2 could be
modulated by phosphorylation at T18, whereby the affinity of
the phosphorylated p53 peptide may be enhanced by compensatory mutations of the Y67, D68 and E69 residues [88]. In addition,
thermodynamics and kinetics of p53-MDM2 binding can be
controlled by functional dynamics of the gate-keeper MDM2
residue Y100 [89]. The effect of chemical modifications in the lid
on p53-MDM2 binding was initially addressed using MD
simulations of the N-terminal apo-MDM2 domain [90]. This
study has for the first time attempted to model the complex
relationship between the MDM2-mediated regulation of p53
binding, the MDM2 lid dynamics and a chemical state of
phosphorylatable residues. Nevertheless, this investigation could
not yield an intrinsically consistent thermodynamic model that
simultaneously satisfied conflicting observations from NMR
[55,57] and biochemical studies [61,62]. Biophysical modeling
studies have successfully reproduced the experimental trends in
binding affinities with MDM2 for a large variety of p53 peptides
[91]. MD simulations have been also used to rationalize the
differences in binding of p53 and nutlin-3 to the MDM2 and
MDMX receptors, revealing that p53 may be displaced from
MDM2 by nutlin-3 because of the larger entropic penalty upon
sequestration from MDM2 [92]. Molecular docking with multiple
MDM2 crystal structures using a receptor-based pharmacophore
model has identified binding hotspots and assisted in the discovery
of high-affinity small-molecule inhibitors [93]. MD simulations
combined with molecular mechanics generalized Born surface
area (MM-GBSA) analysis have successfully predicted the relative
MDM2 binding affinities for a number of p53 analogues,
including regulatory phosphorylation, p53 mutations and truncations [94–102]. Mechanistic and thermodynamic effects of Cterminal MDM2 mutations have revealed distinct mechanisms for
modulating binding affinity that could guide the design of targeted
peptidomimetics and small molecules [103]. Overall, integration
of computational and experimental approaches has become
a viable strategy in the discovery of MDM2 inhibitors targeting
p53-MDM2 binding [104,105].
Despite the growing body of structural and functional experiments, mechanistic and dynamic aspects of MDM2-mediated
regulatory mechanisms remain rather confusing, owing in part to
conflicting data produced in NMR [55,57] biochemical [61,62]
and biophysical studies [63]. Particularly intriguing recent
evidence has indicated that structural and functional impact of
posttranslational lid modifications may be affected not only by the
length of the p53-based peptides, but be also influenced by the lid
construct and its size [63]. In this work, we propose a unifying
3
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theoretical model capable of reconciling structural, biophysical
and computational studies. An integrative computational analysis
is employed to simulate structure, dynamics and energetics of apoMDM2 as a function of posttranslational modifications. Similarities and differences in functional dynamics of apo-MDM2 with
the complete and truncated lids are also analyzed. We show that
a conformational selection model of preexisting MDM2 states can
provide a unifying mechanistic principle of MDM2 dynamics and
reveal an important functional role of the lid in dynamic
regulation of MDM2 functions.

mobility of the lid segment 21-ASEQ-24 is in agreement with
NMR studies [57], demonstrating that these residues may have
order parameters as high as those of the MDM2 core domain. A
different picture emerged from simulations of the phosphomimetic
S17D form (Figure 3). Whereas the thermal fluctuations of the
MDM2 domain remained stable within a similar fluctuation range
of RMSD = 1Å, the closed form of the S17D lid, that persisted
during first 5 ns, transitioned towards the ensemble of more
mobile, ‘‘semi-closed’’ conformations. (Figure 3A, B). Conformational mobility of these conformations was reflected in the
relatively large RMSF = 2.5 Å values of the mutated lid
(Figure 3C). These simulations quantified the effect of posttranslational lid modifications and tested the initial conjecture,
according to which phosphorylation of the S17 lid residue may
enhance lid binding and thus inhibit the p53-MDM2 interactions
[55]. On the simulation time scale, the equilibrium ensemble of
apo-MDM2 with the truncated lid (residues 16–24) fluctuated
primarily between semi-closed and closed states (Figure 4A),
which agrees with the thermodynamic preferences towards the
closed form [55,57]. According to NMR-based study of (172125)
MDM2 [57], functional dynamics of the N-terminal lid can
involve slow exchange (.10 ms time scale) between a dominant
‘‘closed’’ form and largely disordered ‘‘open’’ states. It is therefore
consistent with the NMR experiments that on a nanosecond time
scale of MD simulations the truncated lid would fluctuate near the
closed state (Figure 4). We found that functional dynamics and
the intramolecular interactions of the truncated lid could alter
significantly in response to posttranslational modifications at S17.
Indeed, MD simulations of the phosphorylated MDM2-pS17 form
(Figure 4B) exhibited minor thermal fluctuations and structural
stability of the pS17 lid, which reflected thermodynamic preferences towards a more ordered, ‘‘closed’’ lid form (Figures 4B,
S1). On the other hand, the phosphomimetic S17D mutation may
have a more subtle yet an appreciable functional effect on the lid
dynamics, biasing the thermodynamic equilibrium towards an
ensemble of more flexible, ‘‘semi-closed’’ conformations
(Figure 4C). Mutation-induced changes in the equilibrium
dynamics promote thermal fluctuations over a larger conformational space and are characterized by more frequently interconverting ‘‘closed’’ and ‘‘semi-closed’’ lid states (Figures 4C,
S2). These observations are consistent with NMR experiments
[55,57] and demonstrate that the increased structural stability and
the closed lid may be favored by the phosphorylated MDM2 form,
whereas the phosphomimetic mutation may adjust thermodynamic preferences towards more structurally mobile conformations.
Overall, our findings indicated that chemical modifications of the
lid at phosphorylatable sites may serve as dynamic regulators of
the thermodynamic equilibrium between preexisting conformational states of apo-MDM2.
MD simulations of the apo-MDM2 protein with the complete
lid representation (residues. 1-MCNTNMSVPTDGAVTTSQIPASEQ-24) revealed a similar stability of the core domain
(residues 25–109) (Figure 5). However, we observed very
significant fluctuations of the lid conformations regardless of the
chemical modifications at S17. These findings reflected the lack of
meta-stable lid intermediates interacting with the MDM2 binding
cleft. In agreement with the NMR studies [56], we found that
a functional segment of the lid 21-ASEQ-24 may occasionally
adopt helical-like conformations and form weak interactions with
the binding cleft. However, these conformations were typically
transient and short-lived, followed by a rapid dissociation of the lid
from the binding site into a fully disordered state (Figure 5).
Overall, the conformational lid ensemble of apo-MDM2 was
highly diverse irrespective of the chemical state of the lid, where

Results
MD Simulations of apo-MDM2
Several models were initially proposed to explain mechanisms of
the p53-MDM2 interactions and regulation of p53 (Figure 1).
The first model invoked a conformational change in the
interacting p53-helix upon phosphorylation of p53-T18 which
could lead to the reduced affinity for MDM2 [49–51]. The
alternative model suggested the role of the phosphorylated residue
S17 as a functional regulator of MDM2 interactions by inducing
a ‘‘closed’’ lid conformation which is capable of competing with
p53 for binding with MDM2 [55]. According to this model, rapid
phosphorylation of the MDM2-S17 residue, followed by phosphorylation of p53-T18, would make the displacement of the
MDM2 lid difficult due to a close proximity of the phosphate
groups and result in the eventual repulsion of p53. To elucidate
structural and dynamic aspects of the MDM2-mediated regulation
of p53, we employed a synergistic modeling approach that
combined all-atom MD simulations and analysis of the equilibrium conformational ensembles with molecular docking, structural
clustering and binding free energy analyses of the low-energy
structures. MD simulations of the N-terminal domain of apoMDM2 using a truncated functional lid (residues 16-TSQIPASEQ-24) [55,57] and a complete lid (residues 1–24) [56,63] were
carried out for the wild type (WT) form, the phosphorylated form
MDM2-pS17, and the phosphomimetic form MDM2-S17D. The
following specific objectives were pursued in MD simulations : (a)
perform a comparative analysis of the equilibrium conformational
ensembles using both complete and truncated lid representations;
(b) elucidate the role of phosphorylation and phosphomimetic
mutation on the mechanism of MDM2 regulation; (c) quantify the
effect of the lid size ((162125)MDM2 [55], (172125)MDM2 [57],
(1–125) MDM2 [63]) on functional dynamics and the intramolecular regulatory interactions; (d) identify key functional residues
and interactions that control dynamics and regulation of MDM2
binding.
To quantify the effect of the lid size and better understand the
mechanism of intramolecular MDM2 regulation, we first performed MD simulations using the truncated lid variant (residues
16–24) that was employed in a series of pioneering NMR studies
[55,57]. The time dependent evolution of MD trajectories was
monitored using the root mean square deviation (RMSD) for all
backbone atoms. Conformational mobility analysis revealed the
enhanced stability of the MDM2 core domain (Figure 2A) and
the lid (Figure 2B) in simulations of the phosphorylated MDM2pS17 form. MD simulations were generally stable within
a fluctuation range of RMSD = 1Å for the core domain and
RMSD = 2Å for the lid. The protein flexibility variations were
also evaluated from the root mean square fluctuation (RMSF)
values of the backbone residues (Figure 2C). The thermal
fluctuations of the MDM2 lid were reduced in the phosphorylated
form and more evenly distributed among lid residues as evidenced
by the RMSF values (Figure 2C). The observed restricted
PLoS ONE | www.plosone.org
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Figure 1. Models of the MDM2-mediated Regulation Mechanisms. (A) The first model assumed a conformational change in the N-terminus
amphipathic helix of p53 upon phosphorylation of T18. According to this model, conformational changes in p53 could reduce binding affinity and
result in the eventual disruption of the p53-MDM2 interactions. (B) The second model suggested the role of phosphorylation at S17 in displacing the
phosphorylated p53 from the binding site. A simultaneous in-vivo phosphorylation of T18 and S20 on p53 and S17 on the MDM2 lid can bring the
negatively charged phosphates on these residues in a close proximity leading to the abrogation of the p53-MDM2 interactions.
doi:10.1371/journal.pone.0040897.g001

apo-MDM2 may be too short-lived to produce NOEs. The
important computational investigation by Dastidar et al [90] has
proposed that phosphorylation may drive the intramolecular
interactions between the lid residue D11 and K94, thus stabilizing
the closed lid form occluding the binding cleft. In our simulations,
we could not detect a significant accumulation of meta-stable
intermediate states, where the lid residues 2–18 formed interactions with the binding site. According to our findings, conformational ensembles were characterized by short-lived intramolecular

‘‘open’’, ‘‘partly open’’ and ‘‘partly closed’’ lid states displayed
a considerable degree of disorder and interconverted on the
simulation time-scale (Figures 5). In agreement with the latest
biophysical investigations [63], our simulations of apo-MDM2 (1–
125) indicated that the lid can form a mobile, ‘‘partly closed’’ form
and participate in transient intramolecular interactions independent of the chemical transformations at S17. These results are also
in accordance with the NMR studies [56], which suggested that
the interactions between the N-terminal lid and the binding cleft of

Figure 2. MD Simulations of the Phosphorylated pS17 MDM2 form. MD simulations were carried out using a truncated lid form (residues 16–
24). The RMSD fluctuations of the Ca atoms of the core MDM2 domain residues 25–109 (A) and the MDM2 lid residues 16–24 (B) obtained from 10 ns
MD simulations of the phosphorylated pS17 form. (C) The RMSF values of the Ca atoms of the core MDM2 domain residues 25–109 (shown in red)
and the MDM2 lid residues 16–24 (shown in blue) obtained from 10 ns MD simulations of the phosphorylated pS17 form.
doi:10.1371/journal.pone.0040897.g002

PLoS ONE | www.plosone.org
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Figure 3. MD Simulations of the Phosphomimetic S17D MDM2 Form. MD simulations were carried out using a truncated lid form (residues
16–24). The RMSD fluctuations of the Ca atoms of the core MDM2 domain residues 25–109 (A) and the MDM2 lid residues 16–24 (B) obtained from
10 ns MD simulations of the phosphomimetic S17D form. (C) The RMSF values of the Ca atoms of the core MDM2 domain residues 25–109 (shown in
red) and the MDM2 lid residues 16–24 (shown in blue) obtained from 10 ns MD simulations of the phosphomimetic S17D form.
doi:10.1371/journal.pone.0040897.g003

interactions formed by residues 19-IPASEQ-24 largely irrespective
of the chemical state of the lid at S17. At the same time the rest of
the N-terminal lid was largely disordered and deviated away from
the binding cleft (Figure 5). These results are supported by the
NMR findings [56] which indicated the absence of long-range
NOEs amongst residues 2–18 and ruled out the possibility for

these lid residues to make stable interactions with the p53-binding
groove. In addition, our findings may provide a plausible
structural explanation why p53-MDM2 binding may be weakly
dependent on the phosphorylation state as observed in biophysical
studies with the complete apo-MDM2 construct [63]. Conformational ensembles of the truncated and complete lid exhibit

Figure 4. Mutation-induced Modulation of the MDM2 Conformational Ensembles: A Truncated Lid Model. Structural clustering of MD
trajectories from simulations with a truncated lid (residues 16–24). The effect of phosphorylation and mutation-induced modulation of the
conformational ensembles is illustrated for MDM2-WT (A), MDM2-pS17 (B) and MDM2-S17D (C). The apo-MDM2 (16–109) construct was used in all
simulations. The representative MDM2 conformations from 10 dominant clusters were subjected to subsequent structural refinement by global
minimization of the complete MDM2 structure. A ribbon-based representation of the MDM2 conformational ensembles was used. Coloring is
according to the B-factors values (blue-to-red spectrum) reflecting protein nobilities of the MDM2 residues (from more rigid-blue regions to more
flexible-red regions).
doi:10.1371/journal.pone.0040897.g004
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integrity and thermodynamic stability of the ‘‘closed’’ lid form
(Figure 6). When S17 is phosphorylated, the negatively charged
phosphate of pS17 can form strong salt bridges with K94. The
stability of these interactions was also reflected in a rapid transition
to the thermodynamically dominant ‘‘closed’’ form after 2 ns
(Figure S4A). After a salt bridge between pS17 and K94 was
established, the binding cleft of MDM2 was completely shielded
by the lid and remained in this state throughout the simulation
period. The hydrogen bond interactions formed by the pS17
phosphate group with K94, H73 and Q72 of the MDM2 core
domain were also stable and maintained in the course of
simulations (Figure S4). In particular, the most stable contacts
were pS17-K94 (95% occupancy), pS17-H73 (90% occupancy),
S22-R97 (82% occupancy) and E23-K51 (78% occupancy). Other
specific contacts included S17-K96 (55% occupancy), E25-K51
(55% occupancy), and hydrogen bond between Q18 and the
backbone carbonyl oxygen of Q72 (53% occupancy) (Figure 6).
These interactions were further supported by the favorable
contacts of the A21 backbone with the H96 and R97 residues.
The hydrogen bonding network was accompanied by the favorable packing interactions formed by the lid with the L54, H96 and
Y100 residues of the MDM2 binding cleft.
The pattern of stable specific interactions formed by the lid in
the binding cleft was partly altered in simulations of the S17D
mutant. Importantly, the occupancies of the key salt bridges S17DK94, S17D-H73 and E23-K51, responsible for preserving the
stability of the ‘‘closed’’ lid conformation, were markedly reduced
(Figure 6). The weakened interactions with K94 and K51 were
primarily due to the larger fluctuations of the S17D lid and the
increased population of ‘‘semi-closed’’ conformational states. The
occupancy of S17D-K94 was reduced to only 20% and E23-K51
to about 15%. The altered pattern of stabilizing interactions was
also accompanied by repositioning of the hydrogen bonding
formed by S17D towards the H96 side-chain (Figure S4B). The
occupancy of the hydrogen bonding between Q18 of the lid and
Q72 of the core domain was also reduced, thus reflecting the
change in the interaction network and partial opening of the
binding cleft. Additionally, the carbonyl oxygen of A21 was
hydrogen bonded to H96 with 30% occupancy, and with the gatekeeper residue Y100 with 25% occupancy. As a result, the gatekeeper Y100 residue may become less constrained by the

considerable differences in the mobility and intramolecular
interactions (Figure S3A). While the lid construct (16–24) could
form a stable interface with the binding cleft and closely mimic
p53-MDM2 interactions (Figure S3B), the full length lid (1–24)
revealed a highly flexible ensemble of rapidly dissociating
structures that typically form only weak, transient interactions in
the binding site. Despite important differences in functional
dynamics of apo-MDM2 as a function of lid length and
composition (Figure 5), we found that the dynamic equilibrium
between ‘‘closed’’, and ‘‘semi-closed’’ (or ‘‘partly closed’’) lid forms
may be a fundamental characteristic of MDM2 regulatory
interactions, which can be modulated by phosphorylation,
phosphomimetic mutation as well as by the lid size. The mobile,
yet partly closed lid form and weakened dependence on the
phosphorylation can provide a rationale for binding of small p53based peptides and inhibitors without direct competition with the
lid dynamics. The central finding of our simulations revealed that
such dynamic lid model is structurally and thermodynamically
plausible, as well as consistent with diverse structural and
biophysical experiments results [55–57,63]. It is worth noting that
our results do not support an alternative ‘‘open’’ model which
suggested a positive regulatory role of the lid in p53-MDM2
interactions [61,62].

Hierarchy and Dynamics of Stabilizing Interactions: The
Effect of Chemical Modifications in the MDM2 Lid
In the previous section, we concluded that the stability and
dynamics of the intramolecular regulatory interactions may be
better characterized and quantified using the truncated lid variant.
Here, we analyzed functional dynamics of apo-MDM2 and the
effect of chemical modifications in the lid to provide a detailed
comparison and rationalization of NMR experiments where the
respective apo-MDM2 variants (16–125) [55] and (17–125) [57]
were studied. In general, lid residues 16-TSQIPASEQ-24 could
form a number of favorable interactions in the MDM2 binding
cleft, which is rich in charged residues (K51, K64, R65, Y67, K70,
K94, R97, and K98). The high average occupancies of specific
interactions formed by the lid with K94, H73 emerged as an
important characteristic of the phosphorylated MDM2-pS17
form. These interactions are likely to be responsible for structural

Figure 5. Mutation-induced Modulation of the MDM2 Conformational Ensembles: A Complete Lid Model. Structural clustering of MD
trajectories from simulations with a complete lid (residues 1–24). The effect of phosphorylation and mutation-induced modulation of the
conformational ensembles is illustrated for MDM2-WT (A), MDM2-pS17 (B) and MDM2-S17D (C). The complete apo-MDM2 (1–109) construct was
used in simulations. The representative lid conformations are colored in red (residues 1–15) and cyan (residues 16–24). A ribbon-based representation
of the MDM2 core domain was used.
doi:10.1371/journal.pone.0040897.g005
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Figure 6. The Distribution and Occupancy of Specific Lid-Receptor Interactions. The distribution of the high occupancy contacts and salt
bridges obtained from MD simulations of the phosphorylated MDM2-pS17 and phosphomimetic MDM2-S17D lid. The occupancies for pS17 are
shown in blue filled bars and S17D in red filled bars. The analysis is focused on the dynamics of specific interactions formed by the lid with the core
domain of MDM2. The intra-domain salt bridges are not included. The distance cutoff for hydrogen bonding is 3.50 Å and the angle cutoff is 120.00
degrees.
doi:10.1371/journal.pone.0040897.g006

interactions with the MDM2 lid and adopt the ‘‘open’’ (‘‘out’’)
state, thereby facilitating ligand access to the binding cleft [89].
These alterations in the network of stabilizing interactions
reflected a shift in the thermodynamic equilibrium of MDM2S17D towards the ensemble of ‘‘semi-closed’’ lid conformations.
Collectively, these structural changes could promote a partial
opening of the binding cleft making it accessible for inhibitors
without interfering with the lid dynamics (Figure 4C).
We found that the dynamic equilibrium between ‘‘closed’’ and
‘‘semi-closed’’ lid forms is a common driver and determinant of
MDM2 regulatory interactions. Thermal fluctuations between
these forms were typically reflected in strengthening or weakening
the key intramolecular interactions with K94/H73, without
requiring global conformational changes. These results are in
accordance with the NMR studies, suggesting that the phosphomimetic S17D can induce the ‘‘closed’’ lid form and block the
MDM2 binding cleft from p53 [55,57]. An alternative mechanistic
model suggested that S17D could induce opening of the binding
cleft by relocating the lid towards the interaction hot spot of
solvent-exposed R97 and K98 residues [61,62]. Computational
studies [90] have also indicated that lid phosphorylation may
induce ensembles of structurally distinct conformations driven by
formation of salt bridges with K51, K94 or R97/K98 residues.
Our results may explain conflicting experimental observations
without assuming structural reorganization and migration of the
lid away from the binding site. The proposed model suggested that
large structural rearrangement of the lid may not be necessary to
vacate the portion of the binding cleft sufficient for binding of
small molecules. Structural reorganization of the lid required to
establish hydrogen bonding of pS17 (or S17D) with a patch of the
remote surface residues R97 and K98 may be disfavored on the
thermodynamic grounds, irrespective of the lid size and compoPLoS ONE | www.plosone.org

sition. Indeed, conformational transformations to form a new
intramolecular interface would inevitably involve breaking the
binding site interactions and require desolvation of the charged
and highly exposed surface residues.

Functional Coupling of the S17 Phosphorylation and
Y100 Gating in Modulating Conformational Ensembles of
MDM2
It was previously proposed that gating dynamics of MDM2Y100 between ‘‘in’’ and ‘‘out’’ conformations may control ligand
access to the MDM2 binding cleft and influence the kinetics of p53
binding [89]. We conjectured that mutation-induced lid dynamics
may be functionally coordinated with the gating dynamics of Y100
in modulating conformational ensembles and regulation of
MDM2 binding. According to our results, the closed structure
of the MDM2-pS17 lid could recruit the ‘‘in’’ conformation of
MDM2-Y100 to optimize the interactions in the binding cleft
(Figure S5A). In support of the functional coupling between the
S17 and Y100 residues, we also found that mutation-induced bias
of the S17D lid towards an ensemble of ‘‘semi-closed’’ conformations could be accompanied by rotation of the gate-keeper Y100
towards the open (‘‘out’’) conformation (Figure S5B). Hence,
functional coupling between the lid dynamics and gating dynamics
of Y100 can collectively coordinate opening of the binding cleft to
allow access of p53-based peptides and small molecule inhibitors.
The MDM2 inhibitor nutlin-3 mimics the interactions of the
p53 triad (L26, W23 and F19) in the binding site with all three
hydrophobic pockets of the receptor [58,59]. According to our
results, the closed conformation of the phosphorylated pS17 lid
can severely interfere with nutlin-3 binding (Figure S6 A, B). In
particular, P20 of the closed lid would overlap with the

8

July 2012 | Volume 7 | Issue 7 | e40897

Computer Simulations of MDM2 Regulatory Mechanisms

number of rotatable angles and the enormous size of the
conformational space (.200 independent variables) combined
with a highly flexible nature of the lid conformations make
computational prediction of the low-energy states inherently
uncertain and largely intractable. To quantify pseudo-substrate
interactions of the MDM2 lid, we focused our analysis on
structural and energetic predictions of the truncated lid binding as
a function of posttranslational modification and mutation at S17.
The initial unbound lid conformation before docking is shown
in the binding site defined by the N-terminal amphipathic a-helix
of p53 (Figure 7A). Chemical shift data of the MDM2 lid in the
WT form have indicated that residues 21-ASEQ-24 could form
a helical structure [57]. While simulations of the MDM2-WT
supported these observations, we found that the phosphorylated
lid may undergo a partial unfolding upon binding in the region 21ASEQ-24 (Figure 7B). The strengthened interactions of the
phosphorylated lid with all three pockets of the binding cleft and
the increased ordering of residues 16–20 in the closed form may be
fulfilled via partial unfolding of the helical structure for residues
21-ASEQ-24. The restricted movements of the pS17 lid, owing to
the strong interactions with the receptor residues, may require the
P20 residue (which is a strong helix breaker) to mimic interactions
of p53-L26. This could restrict the range of allowed conformations
and constrain the adjacent residues I19 and A21. Hence, our
results suggested that folding-binding coupling in the fragment of
the MDM2 lid may be modulated by the chemical state at S17,
where the P20 residue may be strategically positioned as a key
regulatory element controlling the helix structure. Hence, the
increased order and stability of ‘‘closed’’ lid conformations is
primarily determined by the strong binding preferences of the
truncated lid.
We characterized structural features of the low-energy phosphorylated lid structures using a comparative analysis of the two
dominant lowest energy clusters (Figure S7). We found that the
‘‘closed’’ lid form was a common attribute shared by all major
lowest energy clusters. Despite local differences in the bound lid
conformations and receptor side-chains, the phosphorylated lid
could strongly interact with the three hydrophobic pockets of the
binding cleft (Figure S7). In agreement with MD simulations and
NMR data, the specific interactions seen in all low energy clusters
included hydrogen bonding of pS17 with K94, H73 and Q72
residues as well as the interactions formed by Q18 with the
backbone carbonyl of Q72 (Figures 8,9). Consistent with MD
simulations, pS17 lid conformations could preserve the key salt
bridge formed by the phosphate group with K94 and specific
interactions S22-R97 and E25-K51 that are critical for structural
integrity of the closed lid form (Tables 1 and 2). The extensive
network of hydrophobic contacts was also observed across all low
energy clusters. A fundamental characteristic of the phosphorylated lid binding is a high degree of structural similarity between
the low energy lid conformations and the p53 helix (Figure 8). In
particular, MDM2-Q18 could mimic the hydrogen bond formed
by p53-F19 and the pyrrolidine ring of MDM2-P20 could mimic
the interactions of p53-L26 (Figure 8B). The interactions of the
phosphorylated lid with K94, H73 and Q72 would bring the
phosphate group of pS17 close to the position of p53-T18
(Figure 8C). According to these predictions and consistent with
NMR studies [55], simultaneous phosphorylation of the truncated
lid at S17 and p53 at T18 positions would bring the phosphate
groups on these residues in a very close proximity, thereby likely
interfering with the p53-MDM2 interactions. It was previously
shown that phosphorylation of p53-T18 can weaken p53-MDM2
binding by ,10-fold as compared to phosphorylation of p53-S20
[10,11]. In agreement with these experimental findings, we

bromophenyl inhibitor group occupying the p53-L26 binding
pocket, and the nutlin-3 ethyl ether side chain, which is directed
towards the p53–F19 pocket, would directly interfere with the
interactions formed by pS17 and Q18 (Figure S6B). In contrast,
the phosphomimetic S17D mutation may induce a partial opening
of the binding cleft by moving away the stretch of lid residues 16–
20 and altering the network of interactions formed by S17D and
Q18 in the binding cleft (Figure S6C). In the closed lid
conformation, the hydrophobic interactions with the first and
second hydrophobic MDM2 pockets are mimicked by P20 and
I19 of the phosphorylated lid. Upon S17D mutation, these lid
residues tend to move away and vacate their positions in the
binding site, thereby allowing the second bromophenyl group and
the ethyl ether side chain of nutlin-3 to occupy their crystallographic positions (Figure S6 C, D).
The emergence of a ‘‘semi-closed’’ lid form in the equilibrium
ensemble of MDM2-S17D can enable a partial opening of the
binding cleft and allow for initial ligand entry. Additionally, the
mobility of the lid conformations may provide means for
subsequent optimization of MDM2 binding affinities with
inhibitors. According to the proposed mechanistic scenario,
binding of nutlins to MDM2 may proceed via search within the
preexisting conformational ensemble of semi-closed MDM2 states
for suitable low-energy receptor conformations. This may be
followed by an induced-fit adjustment of the low-energy lid
structures to optimize the intermolecular interactions. A model of
‘‘extended conformational selection’’ and conformational sampling of preexisting states [106,107] may thus present a plausible
mechanism of MDM2-mediated regulation by allowing proceeding through a hierarchy of conformational tiers that can be
searched more efficiently than by random sampling of all possible
conformations.

Structural Analysis of the MDM2 Lid Interactions:
Molecular Docking
To compare the equilibrium ensembles of apo-MDM2 with
structural and energetic characterization of the intramolecular lid
binding, we combined MD simulations and molecular docking.
While equilibrium MD simulations may describe a mechanism of
‘‘conformational selection’’ between preexisting conformational
states of MDM2, molecular docking and binding free energy
analysis could more adequately model the induced-fit adjustment
of the low-energy states. Consequently, the following specific
objectives were addressed in docking experiments : (a) predict and
validate the low-energy MDM2 structures by comparison with the
equilibrium conformational ensembles; (b) characterize structural
diversity of low-energy MDM2 structures and determine functional role of structural variations in the lid; (c) quantify pseudosubstrate interactions of the MDM2 lid and characterize the role
of structural mimicry in regulation of MDM2 binding. Molecular
docking of the lid (residues 16–24) with the core domain of the
apo-MDM2 receptor (residues 25–109) was performed by using
replica-exchange Monte Carlo simulations with the ensembles of
multiple MDM2 crystal and NMR structures. To adequately
simulate structure and energetics of the intramolecular lid binding
in apo-MDM2, we employed a ‘‘partially fixed’’ lid model by
constraining the MDM2 lid at a single Ca atom position of Gln25. This model of a flexible lid considered a total of 37 torsional
angles as independent variables during multiple docking runs. As
a result, a very large conformational space was sampled in docking
simulations to characterize the low-energy lid structures. It is
worth noting that molecular docking of the complete lid (residues
1–24) presents a considerably more challenging problem that was
attempted in our studies. However, the dramatic increase in the
PLoS ONE | www.plosone.org
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Figure 7. Folding-binding Coupling of the Phosphorylated pS17Lid. (A) The initial ‘‘open ‘‘conformational state of the lid shown over the
p53 binding surface of MDM2 receptor. The three hydrophobic pockets (I, II, III) the receptor are occupied by respective p53 residues L26, W23 and
F19 respectively in the p53-MDM2 complex. (B) The ‘‘closed’’ conformational state of the lid. Conformational changes in the MDM2 receptor and the
phosphorylated lid upon binding are depicted. Structural restructuring and partial unfolding of the structured turn in the lid upon binding is
highlighted in magenta. Positions of P20 and I19 on the MDM2 surface and phosphorylated S17 near K94 and H73 are also shown. Residues around
the p53-binding site which undergo large conformational change upon lid binding are highlighted.
doi:10.1371/journal.pone.0040897.g007

S17D-H96 interactions. However, other specific contacts between
Q18 and Q72 were preserved, being largely responsible for the
formation of the ‘‘semi-closed’’ lid form. A more drastic structural
reorganization was observed in the alternative low energy cluster
marked by the alteration of all three critical contacts with K94,
H73, and Q72 (Figure S8). Some of these contacts may be only
partly compensated by the contacts formed by S17D and Q18
with H96. In this low-energy structure, the phosphomimetic lid
may open up a larger portion of the binding cleft by migrating
most of the contacts away from the K94 and H73 residues toward
H96.
The predicted structural models of the phosphorylated lid
reflected the adjustment and refinement of the lid and core
domain residues within the closed form. According to our results,
the hydrophobic receptor residues near the binding pocket move
side-chains to optimize their interactions with the phosphorylated
lid (Figures 10, 11). We observed the appreciable side chain
movements (.2 Å) in M50, K51, M62, Q72, K94, H96, R97,
K98 and Y100 residues that collectively adjusted their positions to
optimize interactions with the closed pS17 lid. Structural plasticity
of the binding site residues may be determined by coordinated
movements involving relatively small changes in the protein
backbone and large variations of the side–chains (Figures 10,

observed that the phosphate position on pS17 in the low-energy
structures and the position of p53-T18 in the crystal structure of
the p53-MDM2 complex are in closer proximity to K94 and H73
than p53–S20 (Figure 8C). Hence, structural predictions suggest
that a pseudo-substrate autoinhibitory mechanism may regulate
p53-MDM2 binding. The key structural feature of the binding
interface is the hydrogen bonding network formed by pS17 and
Q18 with K94, Q72 and H73 residues (Figure 9B). In addition,
structural position of P20 occupying the first hydrophobic pocket
(Figure 9C) would likely make the carbonyl oxygen of the
adjacent residue more electronegative, with the enhanced
tendency for hydrogen bonding. Indeed, that carbonyl oxygen
of A21 could form a strong hydrogen bond with R97 (Figure 9C).
A partial constriction of the second binding pocket may also
explain why I19 could not fully project inside the cleft
(Figure 9D). A somewhat different pattern of the low-energy
lid conformations emerged from docking simulations of the S17D
mimetic lid (Figure S8). Unlike the phosphorylated lid, we
observed that S17D may induce structural deviations of the
residues 16–20 from their closed conformation. In one of the
lowest energy states with a moderate conformational change
(Figure S8), the interaction pattern was altered by breaking the
hydrogen bonding with K94 and H73 and replacing it with the

PLoS ONE | www.plosone.org
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Figure 8. Structure-Functional Analysis of MDM2 and p53 Phosphorylated Sites. (A) A network of hydrogen bonding and hydrophobic
interactions formed by the phosphorylated pS17 lid with the MDM2 core domain in the lowest energy structure. Functional importance of the
conserved lid residues is illustrated. (B) An overlay of the p53 peptide (brown) with the phosphorylated flexible lid (dark red). The p53 residues L26 (in
blue), W23 (in cyan), F19 (in magenta), and T18 (in pink) are shown in ‘sticks’, while corresponding residues of the phosphorylated lid when bound to
MDM2 are shown in ‘ball-and-sticks’. Structural proximity of the phosphorylated pS17 of the lid to p53-T18 could be seen. (C) Structural proximity of
the phosphate on the MDM2-pS17 lid (in ball-stick-model with atom-based coloring) and the phosphorylated positions on p53-T18 and p53-S20 (in
ball-and-stick model colored in blue) is highlighted. The lowest energy structure of MDM2-pS17 (in green ribbons) is aligned with the crystal structure
of the p53-MDM2 complex (in cyan ribbons).
doi:10.1371/journal.pone.0040897.g008

11). According to our results, this may be sufficient to optimally
accommodate structural and chemical variations in the lid.
Structural similarity between the receptor backbone in the bound
lid structures and the p53-MDM2 complex is in agreement with
NMR studies [57]. Hence, our results are consistent with the
notion that global conformational changes in the MDM2 receptor
may not be required for binding of p53-derived peptides and small
molecule inhibitors [57,63].

interactions that position the phosphorylated lid in the binding
site to mimic p53-helix are also preserved. These interactions that
are formed by Q24 with M50 and E25 with K51 may anchor the
rest of the lid and provide an additional stabilization of the closed
lid structure (Tables 1, 2).
We also compared the contact map of the p53-MDM2
interactions in the crystal structure with the contact map of the
phosphorylated lid interactions in 5 different low energy conformational clusters (Figure 12). These contact maps revealed
a striking similarity in the interaction networks formed by p53 and
the phosphorylated lid conformations with the MDM2 receptor.
The circle size signifies the number of structures forming exactly
the same interaction, and it could be observed that the most
consistent contacts made by the phosphorylated pS17 are with
H73, K94, Q72 and only in one low-energy solution pS17 is in the
contact with H96 (Figure 12). In contrast, the largest variation
could be seen in the binding pattern of the N-terminal residue
T16. According to the p53-MDM2 interactions network topology,
p53-T18 is in the close proximity of Q72, while S20 is in the
contact with M62.
A comparison of the contact maps could also illustrate that the
phosphorylation of Ser17 in the truncated lid would have a more
pronounced effect on p53-MDM2 binding when p53-T18 is
phosphorylated as compared to the phosphorylation effect at p53S20. The contact maps also indicated that similar interactions can
be formed with the same set of evolutionary conserved MDM2
residues [81,82]. These results supported the long-standing notion

Molecular Mimicry of Pseudo-Substrate Lid Interactions
In this section, we characterize the interaction networks and key
lid residues involved in the intramolecular regulation of MDM2.
This analysis allowed to rationalize at the atomic level the
observations from NMR experiments where the respective apoMDM2 variants (16–125) [55] and (17–125) [57] were investigated. Structural similarity between the p53-MDM2 interaction network and the phosphorylated lid interactions in the
binding cleft (Tables 1, 2) is a key functional feature reflecting
conservation of the interaction networks with the MDM2 receptor
(Tables 1, 2). The electrostatic and hydrogen bonding interactions made by E17, F19, E28 and N29 of p53 are replaced
respectively by pS17, Q18, E23 and Q24 residues of the lid. The
hydrophobic p53 interactions in the first and second hydrophobic
pockets are mimicked P20 and I19 of the phosphorylated lid.
Many common MDM2 residues, including L54, L57, G58, I61,
M62, V93, H96 and I99, are involved in the hydrophobic contacts
with p53 and the pS17 lid. Moreover, the ‘‘anchoring’’
PLoS ONE | www.plosone.org
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Figure 9. The Interaction Network of the Predicted Closed Form for the Phosphorylated pS17 Lid Interactions with MDM2. (A) The
‘‘anchoring’’ interactions of the phosphorylated lid formed by E23, Q24 and E25 residues K51 and Y100 core domain residues. E23 and E25 are shown
in red sticks, K51 in blue sticks, Q24 and Y100 in light blue sticks. (B) The hydrogen bonds formed by pS17 and Q18 with K94, Q72 and H73 residues.
PS17 is shown in ball-stick-model with atom-based coloring, K94 in blue sticks. (C) These interactions were further supported by the favorable
contacts of P20 occupying the first hydrophobic pocket and A21 backbone with the H96 and R97 residues. The hydrogen bonding network is
supported by the packing interactions of the lid with the L54, H96 and Y100 residues. (D) The MDM2 residues L54, L57, G58, I61, M62, V93, H96 and
I99 are involved in the hydrophobic contacts of both p53 and pS17 lid. I19 is not projected towards the binding cleft; because of it restricted
movement due to P20.
doi:10.1371/journal.pone.0040897.g009

Table 1. A comparison of the p53 and phosphorylated lid interactions with MDM2.

P53
residue

MDM2 residue hydrogen
bond contact

E17

K94

F19

Q72

MDM2 residue hydrophobic
contact

Lid residue

MDM2 residue hydrogen
bond contact

MDM2 residue
hydrophobic contact

pS17

K94,H73

I61,M62,Y67,V75

Q18

Q72

V93

I19

M62,V93

L57,G58,I61,V93

P20

L54,V93,I99

L26

L54,H96,V93

A21

P27

M50,L54,Y100

S22

R97

E23

K51

L22
W23

L54

E28

K51

N29

Y100,Y104

H96,R97

Q24

M50,Y100,Y104

E25

K51

doi:10.1371/journal.pone.0040897.t001
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phosphorylation state and compared these estimates with
binding free energies of the p53-MDM2 complex.
A simplified knowledge-based model and a detailed MM-GBSA
model were employed (Tables 3, 4). Binding free energies
estimates using the empirical scoring model averaged the energy
contributions over the low energy clusters. DGbinding of the p53MDM2 complex was 25.72 kcal/mol using the knowledge-based
scoring function (Table 3) and 27.3 kcal/mol using the MMGBSA energy function (Table 4) which is in agreement with the
experimental data (DGbinding 26.6 to 28.8 kcal/mol) [82]. The
estimated binding free energy of the pS17 lid with the MDM2 core
domain (DGbinding <210.0 kcal/mol) suggested that the phosphorylation at S17 would give rise to the energetically more
favorable closed form of the truncated lid that may displace p53
binding on thermodynamic grounds (Tables 3, 4). The energetic
decomposition of the binding free energy differences revealed that
the free energy factors may act concertedly to enhance the binding
affinity of the phosphorylated lid. The binding of the p53 helix is
mainly driven by the van der Waals interactions formed by F19,
W23 and L26 of p53. Although the two hydrophobic residues I19
and P20 of the phosphorylated lid mimic the p53-MDM2
interactions, the hydrophobic contribution of p53 binding is more
favorable, partly due to insufficient penetration of I19 into the
binding cleft. Despite the ordered conformation of the phosphorylated lid, the entropic penalty was found to be comparable to p53
using the knowledge-based scoring function (Table 3) and
somewhat larger according to more accurate MM-GBSA
estimates (Table 4). These results indicated that the truncated
lid can adopt optimal structural arrangements in the binding cleft
without a large entropic penalty. The hydrogen bonding, the
electrostatic and the van der Walls interactions were more
favorable for the pS17 lid, suggesting that specific lid interactions
in the binding cleft may be a critical energetic factor in allowing to
displace p53-MDM2 binding. These results agreed with the
previous experimental studies [76,77] and computational investigations [82,95], suggesting an important role of the van der Waals
contribution in driving binding affinities with MDM2.
We found that the electrostatic and hydrogen bonding terms
favoring the lid closure over the binding cleft could not be
completely screened by the unfavorable desolvation contribution
(Tables 3, 4). The binding preferences of the pS17 lid are
determined by a ‘‘concerted effort’’ of both hydrogen bonding and
the van der Waals interactions. By adopting a thermodynamically
favorable closed form, the truncated lid may act as a small ligand
and effectively compete with p53 (17–29) binding because of
comparable entropic penalty upon sequestration from MDM2.
The binding free energy of the phosphomimetic S17D lid was also
evaluated using the empirical scoring based on the low-energy
clusters of docked conformations. DGbinding was in the range
between 26.55 kcal/mol, when using the empirical scoring
function (Table 3), and 27.8 kcal/mol, when using the MMGBSA model (Table 4). The reduced affinity of S17D as
compared to the phosphorylated pS17 analog was mainly due to
the weakening of the hydrogen bonding, the electrostatic and the
van der Waals interactions with the binding cleft (Tables 3, 4).
These estimates reflected the increased structural mobility of the
low-energy lid conformations and a partial loss of the interactions
with the binding site. According to our results, this loss could not
be offset by the reduced entropy penalty and the lowered
desolvation cost upon binding. Hence, while the enthalpy
component may drive favorable binding of pS17, the perturbed
balance of the enthalpy and entropy contributions could lower the
affinity of the phosphomimetic lid, and make it comparable to the
a binding affinity of the p53-MDM2 complex. Our results

Table 2. Molecular mimicry of the p53-MDM2 interactions in
the predicted structure of the phosphorylated pS17 lid.*

MDM2
residue

MDM2
atom

P53
residue

P53
atom

Lid
residue

Lid
atom

H73

HD2

E17

OE2

pS17

O4

K94

2HZ

E17

OE1

pS17

O2

K94

2HZ

E17

OE2

K94

1HZ

pS17

O4

Q72

O

F19

HD1

Q18

2HE2

L54

O

W23

HZ2

K51

3HZ

E28

OE1

E23

OE2

K51

2HZ

E28

OE2

E23

OE1

K51

1HZ

E25

OE1

H96

ND1

A21

H

R97

2HH1

N29

OD1

S22

OG

R97

2HH2

N29

OD1

S22

OG

R97

2HH2

A21

O

Y100

HE12

Q24

OE1

*The table presents the residues and the corresponding atoms of MDM2
receptor which are involved in hydrogen bond formation with p53 residues and
the phosphorylated lid residues.
doi:10.1371/journal.pone.0040897.t002

that molecular mimicry of p53-MDM2 interactions [81,82] is an
important mechanism driving binding of high-affinity mimetics
and small molecule inhibitors [96–105]. Our results indicated that
the intramolecular binding of the functional lid variant (residues
16–24) may utilize elements of molecular mimicry to act as
a natural antagonist to p53 binding. It is worth noting that the
representative conformational ensemble obtained in simulations
with the complete lid construct displayed a shortage of structural
similarity with the p53-MDM2 interactions (Figure S3B). This
observation is consistent with biophysical studies of the complete
apo-MDM2 construct (1–109) [63] and may explain why this lid
form can be readily displaced by p53-based peptides irrespective of
the phosphorylation state.

Energetic Basis of the MDM2 Lid Modulation: Binding
Free Energy Analysis
The first principles analysis of MDM2 binding involves
a comparative characterization of p53 binding thermodynamics
with a panel consisting of the complete MDM2 receptor
(residues 1–109), truncated MDM2 protein (residues 16–109),
and the MDM2 core domain (residues 25–109) as well as
phosphorylated and mutated MDM2 analogues. However, a full
implementation of such approach is computationally intractable
for various reasons, including (a) the lack of crystal structures of
the p53-MDM2 complex with the lid present (in either
truncated or complete form); and (b) the inherent uncertainty
in computing peptide binding free energies in the presence of
long and highly variable lid construct. To understand structure
and energetics of the intramolecular lid-MDM2 interactions, we
modeled the apo-MDM2 structure (residues 16–109) as a hypothetical ligand-protein complex, where the truncated lid
(residues 16–24) was considered as a partially constrained
ligand (at the Ca position of Gln-25) and the MDM2 core
domain (residues 25–109) was used as the protein. We
computed binding free energies of the lid as a function of
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Figure 10. The Lid-based Modulation of Conformational Plasticity in the MDM2 Receptor: Analysis of Side-Chain Movements. Side
chain movements in the MDM2 receptor upon binding of the phosphorylated pS17 lid in 3 lowest energy clusters from docking simulations are
shown in (A), (B) and (C). (D) The RMSD values of the receptor side-chains averaged over 10 lowest energy clusters from docking simulations. The
RMSD of the receptor side-chains were calculated using the crystal structure of the p53-MDM2 complex as the reference state.
doi:10.1371/journal.pone.0040897.g010

confirmed the universality of the enthalpy-entropy compensation
principle that may explain binding preferences of MDM2 for the
phosphorylated lid over p53. The observed pattern of changes in
the enthalpy-entropy compensation upon chemical modifications
in the lid is reminiscent of similar findings made from isothermal
titration calorimetric studies [98], where more favorable entropy
of binding for constrained peptidomimetics was largely offset by
a reduced enthalpy contribution. Conversely, the entropy loss,
often seen in binding of linear p53-derived peptides, may be
compensated by optimized intermolecular contacts and enhanced
enthalpy contribution. Similarly, the high mobility and weakened
intramolecular interactions seen in simulations with the complete
lid should favor its displacement by p53-based peptides of different
length as evidenced from latest biophysical studies [63].

phosphorylation is more pronounced with the truncated lid
variant, favoring the closed form of the MDM2 lid. The dominant
‘‘semi-closed’’ lid form and weakened dependence on the
phosphorylation observed in simulations with the complete lid
can provide a rationale for binding of small p53-based peptides
and inhibitors without direct competition with the lid dynamics.
We have shown that ‘‘extended conformational selection
model’’ is a robust indicator of MDM2 functional dynamics and
may adequately describe mechanism of MDM2 regulatory
interactions. According to the proposed model, molecular
mechanisms of MDM2 binding could be regulated via mutationinduced lid modulation of preexisting conformational states
[106,107]. Our results supported the notion that the organization
of the MDM2 conformational landscape may be separated in
different tiers of protein fluctuations in response to chemical
modifications and ligand binding. As a result, conformational
changes in MDM2 may be hierarchic and combine ‘‘conformational selection’’ among preexisting conformational ensembles,
with a subsequent sub search and induced-fit adjustment. Based on
these findings, we propose that the ‘‘extended conformational
selection’’ model [106,107] of the lid dynamics may provide
a plausible and unifying platform for rationalization of the existing
data. From a thermodynamic perspective, the conformational
selection model and induced fit can be considered as complemen-

Discussion
In this study, we determined that the dynamic equilibrium
between ‘‘closed’’, and ‘‘semi-closed’’ lid forms may be an
important characteristic of MDM2 regulatory interactions, which
can be modulated by phosphorylation, phosphomimetic mutation
as well as by the lid size. Our results revealed that these factors
may regulate p53-MDM2 binding by fine-tuning the thermodynamic equilibrium between preexisting conformational states of
apo-MDM2. In agreement with NMR studies, the effect of
PLoS ONE | www.plosone.org
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Figure 11. The Lid-based Modulation of Conformational Plasticity in the MDM2 Receptor: Analysis of Solvent Accessible Surface
Area Changes. Change in the percentage of the accessible surface area (ASA) of the receptor residues upon binding of the phosphorylated lid in 3
lowest energy clusters from docking simulations (A), (B) and (C). (D) The change in the percentage of ASA for the receptor side-chains averaged over
10 lowest energy clusters from docking simulations. The crystal structure of the p53-MDM2 complex was used as the reference structure. Positive
(negative) values indicate that the residues get more exposed (buried) upon binding of the lid as compared to their position in the crystal structure of
the p53-MDM2 complex.
doi:10.1371/journal.pone.0040897.g011

Figure 12. The Contact Maps of the p53-MDM2 and MDM2-pS17 Interactions. (A) The contact map of the p53 residues with the HDM2
receptor in the crystal structure of the p53-MDM2 complex (PDB ID 1YCR). (B) The contact map of the truncated pS17 lid with the MDM2 receptor in 5
lowest energy structures models. Residues are considered in contact when the minimum inter-residue distance of all pairs of heavy atoms is ,4.2Å. A
comparison indicates a similarity in the nature of the contacts and the contact distances. Larger circles indicate a more probable interaction. The color
coding of the circles indicate the minimum inter-residue distance between the residues and the size signifies the number of conformation forming
the same interaction. Plot has been generated using R package.
doi:10.1371/journal.pone.0040897.g012
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Table 3. Binding free energy calculations of p53-MDM2,
pS217-MDM2 and S17D-MDM2 using a knowledge-based
energy function.*

Table 4. MM-GBSA calculations of binding free energies for
p53-MDM2, pS217-MDM2 and MDM2-S17D.*

Binding Energy

p53-MDM2

MDM2-pS17

MDM2-S17D

DEele

2467.3

2487.4

2470.9

24.56

DEvdw

283.8

288.2

275.9

25.32

DEint

8.6

5.3

6.7

236.51

230.12

DEMM-gas

2542.5

2570.3

2540.1

21.72

20.44

20.87

DGgb-nb

216.4

217.5

218.4

6.81

8.57

5.79

DGgb-pol

484.5

504.6

488.4

DGentropy

33.17

33.1

28.53

DGgb-total

468.1

487.1

470.0

DGtotal

25.72

29.96

26.55

TDStotal

67.1

70.6

62.3

DGtotal

27.3

212.6

27.8

Binding Energy p53-MDM2

MDM2-pS17

MDM2-S17D

DGhydrophobic

27.02

25.85

DGhydrogen

20.02

29.64

DGvdW

236.94

DGelectrostatic
DGdesolvation

bond

21

*All energies are in kcal mol . The contributions of the free energies are
defined in the Materials and Methods section.
doi:10.1371/journal.pone.0040897.t003

*All energies are in kcal mol21. The contributions of the free energies are
defined in the Materials and Methods section.
doi:10.1371/journal.pone.0040897.t004

tary models, as due to thermal fluctuations there is always some
degree of the induced fit on the atomic scale of molecular
interactions. In the framework of this model, the dynamics of
flexible segments may be often separated from the rest of the
protein and evolve on a different time scale. These functional
regions may include pseudo-substrate lid motifs that operate in
a range of allosterically regulated enzymes. According to the
fundamental assertion of the extended conformational selection
model, these fragments (termed ‘discrete breathers’) may regulate
a population-shift between conformational ensembles that accompany binding processes through changes in their mutational status
[106]. Our results also supported the notion that mechanisms of
molecular mimicry and conformational selection may have been
adopted by MDM2 as organizing principles to utilize structural
plasticity for binding to a wide range of protein clients. These
conclusions are consistent with the fact that global conformational
changes in the MDM2 receptor may not be required for functional
diversity of high affinity binding molecules, which may greatly
facilitate the potential of MDM2 to serve as a hub in protein
networks and accommodate interacting partners.
We have shown that an ‘‘extended conformational selection’’
model may explain structural and enzymological data based on
computational analysis of the N-terminal MDM2 domain, thus
bypassing for now the challenge of modeling the full length
MDM2 [90]. However, conformational flexibility of MDM2 and
the existence of multiple binding domains have highlighted the
important role of allostery in regulating the complexity of intraand inter-domain communication. Structurally discrete but interdependent functional domains of MDM2 are allosterically
linked through structural and dynamic changes that are currently
unknown due to lack of structural information. It is tempting to
suggest that the ‘‘extended conformational selection model’’ may
be potentially fruitful to explain functional dynamics of the
interdomain MDM2 regulation. These findings corroborate with
the recent results pointing to a common role of conformational
selection principles in a variety of biological systems [108–111]. It
is possible that a range of allosterically regulated protein hubs
involved in binding with diverse partners, including MDM2
receptors, can adapt to protein clients and ligands by using
a mechanism of equilibrium switching [106,107]. The results of
this work may be useful for probing functions and modeling
mechanisms of MDM2 regulation in signaling cascades modulated
by posttranslational modifications on the p53 regulators. Further
studies connecting diverse experiments with computational studies
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of allosteric signaling and network biology would likely have broad
implications in the development of novel anti-cancer therapies.

Materials and Methods
MD Simulations
We have performed a total of 6 independent 10 ns MD
simulations of the N-terminal domain of MDM2. These simulations were carried out separately using a complete structure of the
lid (residues 1–24) and truncated functional lid (residues 16–24) for
the MDM2-WT, the phosphorylated form MDM2-pS17, and the
phosphomimetic form MDM2-S17D. The initial conformations of
the lid conformations were obtained from the NMR solution
ensemble of apo-MDM2 (PDB ID 1Z1M) [56]. This ensemble
includes a diverse range of states, including both open and closed
lid conformations [56]. To avoid a potential bias in initial
conditions during MD simulations, we selected MDM2 structures
with a disordered lid conformation (corresponding to states 4,
8,9,10 and 11 according to their number in the NMR ensemble
[56]). The missing and unresolved residues were modeled using
the program MODELLER [112,113]. The N-terminal lid variant
(16-TSQIPASEQ-24) was capped at the terminus by the acetyl
cap (CH3-CO-). MD simulations were carried out using NAMD
2.6 [114] with the CHARMM27 force field [115,116] and the
explicit TIP3P water model as implemented in NAMD 2.6 [117].
The VMD program was used for the preparation and analysis of
simulations [118,119]. The employed MD protocol was described
in full details in our earlier studies [120–122]. MDM2 structures
were solvated in a water box with the buffering distance of 10 Å.
Assuming normal charge states of ionizable groups at pH 7;
counter-ions were added to neutralize the total charge of the
system.
The system was subjected to initial minimization for 20,000
steps (40ps) keeping protein backbone fixed which was followed by
20,000 steps (40ps) of minimization without any constraints.
Equilibration was done by gradually increasing the temperature in
steps of 20 K starting from 10 K until 310 K. At each step 15000
steps (30 ps) equilibration was run keeping a restraint of
10 kcal?mol21?Å22 on protein alpha carbons (Ca). Thereafter
the system was equilibrated for 150,000 steps (300ps) at 310K
(NVT) and then for further 150,000 steps (300ps) at 310 K using
Langevin piston (NPT) to achieve uniform pressure. Finally the
restrains were removed and the system was equilibrated for
500,000 steps (1ns) to prepare the system for simulation. An NPT
16
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Molecular docking simulations were performed using replicaexchange Monte Carlo simulations with the ensembles of
multiple MDM2 crystal structures. To expand the conformational ensemble of apo-MDM2 and generate low–energy
conformational states near the native structure, we employed
a self-consistent rotamer optimization [125]. The details of the
docking protocol were detailed in our previous studies
[126,127]. In brief, the molecular recognition energetic model
used in dynamics simulations includes intramolecular energy
terms, given by torsional and nonbonded contributions of the
DREIDING force field [128], and the intermolecular energy
contributions calculated using the AMBER force field [129]
combined with an implicit solvation model [130].The dispersion-repulsion and electrostatic terms were modified to include
a soft core component that was originally developed in free
energy simulations to remove the singularity in the potentials
and improve numerical stability of the simulations [131].
Replica-exchange simulations used 1,000 replicas of the system
(corresponding to 1,000 different snapshots) attributed respectively to 1,000 different temperature levels that were uniformly
distributed in the range between 5300 K and 300 K. The
crystal structures, the ensembles of near-native crystal structure
conformations and MD simulations samples were replicated and
uniformly distributed as a total of 1,000 replicas to 1,000
different temperature levels. Monte Carlo moves were performed simultaneously and independently for each replica at the
corresponding temperature level. A process of swapping
configurations was repeated 100 times after each simulation
cycle for all replicas. For the optimal performance a number of
free parameters such the appropriate temperature distribution,
range of temperatures, number of Monte Carlo sweeps at each
temperature and number of swaps between different temperature levels after each cycle were optimized as previously
documented [126,127]. The lid conformations and orientations
were sampled in a parallelepiped that encompasses the crystal
structures of the MDM2 complexes with a 10.0 Å cushion
added to every side of the box surrounding the binding
interface. The MDM2 core domain structures were held fixed
in their minimized crystallographic conformations, while the
rigid body degrees of freedom and the rotatable angles of the
lid were treated as independent variables during docking.

simulation was run on the equilibrated structure for 10 ns keeping
the temperature at 310 K and pressure at 1 bar using Langevin
piston coupling algorithm. The integration time step of the
simulations was set to 2.0 fs, the SHAKE algorithm was used to
constrain the lengths of all chemical bonds involving hydrogen
atoms at their equilibrium values and the water geometry was
restrained rigid by using the SETTLE algorithm. The van der
Waals interactions were treated by using a switching function at
10Å and reaching zero at a distance of 12Å. Non bonded lists were
updated after 25 steps. The particle-mesh Ewald algorithm (PME)
implementation in the NAMD program was used to simulate long
range electrostatic interactions. Then production runs were
performed for 10 ns (each trajectory) with trajectory frames saved
at 2ps interval. The Pymol program was used for visualization of
protein structures (The PyMOL Molecular Graphics System,
Version 1.2r3pre, Schrödinger, and LLC).

Replica-exchange Monte Carlo Docking Simulations
The Protein Data Bank (PDB) [123] contains a number of
crystal structures of the N-terminus domain of MDM2 (or its
homologues) in the bound and apo forms. However, the Nterminal lid conformation (residues 1–24) is not resolved in most of
these structures. To study the effect of lid binding on the p53MDM2 interactions, we have used the co-crystal structure of the
p53-MDM2 complex (PDB ID 1YCR) [45] as the initial
conformation of the N-terminal MDM2 domain, and attached
the lid residues from the crystal structure of MDM2 with the
benzodiazepine inhibitor (PDB ID 1T4E) [76] to the N-terminus
after structural alignment of the two structures. All publically
available crystal structures of the MDM2 protein from PDB were
used to categorize the conformational space of MDM2, including
the crystal structure of xenopus MDM2 bound to the transactivation domain of p53(PDB ID 1YCQ) [45]; the crystal structure of
human MDM2 bound to the transactivation domain of p53(PDB
ID 1YCR) [45]; the crystal structure of human MDM2 with an
imidazole inhibitor nutlin (PDB ID 1RV1) [58]; the crystal
structure of human MDM2 in complex with a beta-hairpin PDB
ID 2AXI) [64]; the crystal structure of the MDM2 complex with
an 8-mer p53 peptide analogue (PDB ID 2GV2) [65]; the crystal
structures of human MDM2 in the complex with a p53-derived
peptide (PDB ID 1T4F) and a benzodiazepine inhibitor (PDB ID
1T4E) [76]; an ensemble of 24 NMR structures of apo-MDM2
(PDB ID 1Z1M) [56]; and the NMR structure of a complex
between MDM2 and a small molecule inhibitor (PDB ID 1TTV)
[60]. We have also expanded a spectrum of low–energy
conformational states which may mimic a range of protein
equilibrium fluctuations near the native structures. The MDM2
structures were initially prepared by adding the hydrogen atoms
and optimizing their positions. Side chain ionization states were
adjusted to pH 7.0. The computational procedure uses the
penultimate rotamer library [124] to build and optimize multiple
rotamers for the critical MDM2 binding site residues, including
L54, Leu57, I61, M62, Y67, Q72, V75, F86, F91, V93, I99, Y100,
and I103. The energies of the modified protein are optimized
using a simple self-consistent procedure in which optimization of
the rotamer position for a modified residue is followed by the same
procedure for the next mutated residue until convergence is
achieved [125]. We modeled the apo-MDM2 structure (residues
16–109) as a ligand-protein complex, where the truncated lid
(residues 16–24) was used as a partially constrained ligand (at the
Ca position of Gln-25) and MDM2 (residues 25–109) was used as
the protein. The N-terminal lid variant (16-TSQIPASEQ-24) was
capped at the terminus by the acetyl cap (CH3-CO-).
PLoS ONE | www.plosone.org

Binding Free Energy Analysis
The binding free energy of each protein-ligand complex was
estimated using the knowledge-based scoring function [132] which
is a linear combination of the hydrophobic energy contribution,
the electrostatic energy component, desolvation energy of polar
and nonpolar groups, the van der Waals energy contribution, the
internal energy term and the entropy contribution corresponding
to the loss of translational and rotational degrees of freedom. The
solvation terms were fitted to experimental solvation free energies
and the entropy terms were derived from sublimation thermodynamic data. The low energy lid conformations and MDM2
receptor conformations were minimized together as a single
complex by a truncated Newton optimization algorithm and
a gradient cutoff of 0.1 kcal/mol as the termination criteria.
Binding free energy calculations were also carried out using the
molecular mechanics (MM) AMBER force field [133] and the
solvation energy term based on continuum generalized Born and
solvent accessible surface area (GB/SA) solvation model [134–
137]. In MM-GBSA calculations, we employed AMBER99 force
field. The total free energy was given as
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MDM2 and lid coordinates, followed by an additional minimization of the unbound protein and lid.

Gmolecule ~Ggb{total zEMM {TSsolute

Structural Similarity Analysis
We have also employed structural clustering and similarity
analysis of the lid conformations generated in simulations.
Structural similarity metric is based on spatial proximity of the
lid atoms and the atom type. We distinguish hydrogen bond
donors, hydrogen bond acceptors, hydrogen bond donors and
acceptors and nonpolar atoms. The atom type compatibility a(i,j)
is assigned a value between 0.0 and 1.0, with the compatibility
between two atoms of the same type defined to be 1.0 that between
donor and acceptor atom is 0.0. The spatial proximity between
two atoms i and j is evaluated with a Gaussian function
2
2
p(i,j)~10({ri,j =s ) and s~{c2 =log10 (p) where r(i,j) is the
distance between atoms i and j; c~3:0Aand p~0:000032 are
the cutoff distance and proximity threshold respectively. We
calculate a descriptor d(i,j) from the spatial proximity and the
atom type compatibility:

Ggb{total ~Gcavity zGvdw zGgb{pol
In the GB/SA model, the Gcavity and Gvdw contributions are
combined together via evaluating solvent-accessible surface areas:
Ggb{np ~Gcavity zGvdw ~

P

si SAi

i

where Ggb{np is the nonpolar solvation term derived from the
solvent-accessible surface area (SA). Ggb{pol is the polar solvation
energy which is computed using the GB/SA solvation model. A
residue–based cutoff of 8Å is set for computing nonbonded van
der Waals interactions and 20 Å residue–based cutoff is used for
computing electrostatic interactions the values of the interior
dielectric constant and the exterior dielectric constant were set to 2
and 80, respectively. The surface tension coefficient was set to
0.0072 kcal?mol21?Å22. The solute entropy is the sum of the
translational, rotational and vibrational entropy contributions.EMM is the molecular mechanical energy of the
molecule and includes the electrostatic interactions Ees , the van
der Waals contributionsEvdw , and the internal strain energy Eint .
The contributions of the ligand–protein interaction energyDGMM ,
strain energy DGstrain and solvation energy DGGB=SA to the total
binding free energy can be then determined as follows.

d(i,j)~p(i,j)  a(i,j), r(i,j)ƒc

d(i,j)~0, r(i,j)wc
An atom descriptor Dnm (i) for atom i in molecule m is then
calculated by summation over all N atoms in a molecule n
N
P
dmn (i,j). The intermolecular similarity between moleDnm (i)~
j~1

cules m and n is given by the Tanimoto coefficient for a pairwise
comparison of molecules [139]:

DGbind ~Gcomplex {Gprotein {Gligand

M
P

DGbind ~DGinteraction zDGstrain zDGsolvation
S(m,n)~ P
M
The entropic contribution was calculated within the AMBER
module NMODE, where the vibrational entropy contribution
TSvib was evaluated from classical statistical mechanics formula.
Each snapshot was minimized for 100,000 steps in the presence of
a distance-dependent dielectric of 4r(i,j) (where r(i,j) is the
distance between two atoms) until the root-mean-square of the
elements of the gradient vector was less than 561025 kcal mol21
Å21. 100 representative snapshots were used to estimate the
entropy contribution. The binding free energy of complexes was
calculated as follows:

i~1

N
P

n
Dm
n (j)Dn (j)

j~1
2
Dn
n (j) {

j~1

M
P
i~1

n
Dm
m (i)Dm (i){

N
P

n
Dm
n (j)Dn (j)

j~1

Lid conformations are grouped into clusters by comparing the
intermolecular similarity coefficient. The first conformation is
assigned to the first cluster. The next conformation is assigned
to the cluster in which a cluster member has the highest
similarity with the next molecule, if the similarity is above
a threshold, chosen to be 0.85. Otherwise, the next conformation is assigned to a new cluster. The first member of the
a cluster is called the cluster center. After all lid conformations
are assigned to clusters, these conformations are arranged in
new order, starting with the largest cluster and proceeding to
the smallest cluster. The reordered set of lid conformations is
subjected to the same clustering procedure.

Gbind ~Gcomplex {Gprotein {Gpeptide
A practical implementation of this approximation involved
evaluation of the free energies for 1,000 snapshots selected at 10 ps
interval along MD trajectories. The total binding free energy
values were obtained by averaging calculated contributions over
1,000 simulation snapshots at T = 300 K. The binding free energy
evaluations could be performed using either separate trajectories
of the MDM2 complexes, MDM2 core domain and the lid or
a single trajectory [138]. We have used a single trajectory protocol
where the structures for the unbound, lid-free MDM2 core
domain and the lid structures were obtained by separating the
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Supporting Information
Figure S1 The Representative Snapshots from MD
trajectory of MDM2-pS17: A Truncated Lid Model. The
representative snapshots from the 10 ns MD trajectory of the
phosphorylated MDM2-pS17 presented at the time frames of 1 ns
(A), 2 ns (B), 4 ns (C), 6 ns (D), 8 ns (E) and 10 ns (F). The MDM2
conformations are depicted in green ribbons.
(TIF)
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Figure S2 The Representative Snapshots from MD
trajectory of MDM2-S17D: A Truncated Lid Model. The
representative snapshots from the 10 ns MD trajectory of the
phosphomimetic MDM2-S17D presented at the time frames of
1 ns (A), 2 ns (B), 4 ns (C), 6 ns (D), 8 ns (E) and 10 ns (F). The
MDM2 conformations are depicted in cyan ribbons.
(TIF)

bromophenyl nutlin group and the nutlin ethyl ether side chain
interferes with pS17 interactions. (C) Structural alignment of the
semi-closed lid structure from the equilibrium ensemble of the
phosphomimetic S17D lid (in green ribbons) and the crystal
structure of MDM2 with nutlin (in blue ribbons). The position of
the lid is indicated with an arrow. (D) A close-up of the MDM2
binding site reveals that there is no overlap between the S17D lid
(pointed to by an arrow) and nutlin (in blue sticks). The S17D lid
conformation allows the bromophenyl group and the ethyl ether
side chain of nutlin to freely occupy their native positions.
(TIF)

Equilibrium Conformational Ensembles of
MDM2-pS17: A Comparison of the Truncated and
Complete Lid. (A)The representative lid conformations from
the equilibrium ensembles of MDM2-pS17 obtained from
simulations with the complete lid construct (colored in cyan) and
the truncated lid (colored according to the B-factors values). (B)
Structural superposition of the MDM2-pS17 lid conformations
(shown in cyan, a complete lid model) with p53 (shown in blue
sticks).
(TIF)

Figure S3

Figure S4 Time-Dependent History of High Occupancy
Salt Bridges. The time-dependent history of salt bridges
obtained from simulations of MDM2-pS17 (A) and MDM2S17D (B). (A) The depicted high occupancy of the hydrogen bond
interactions in MDM2-pS17 are between the following atoms :
pS17(O2P)-K94(HZ2) in green; pS17(OT)-K94(HZ2) in blue and
pS17()-K94(HZ2) in red. (B) The depicted high occupancy of the
hydrogen bond interactions in the in the MDM2-pS17 is between
S17D (O)-H96 (HE2).
(TIF)

Figure S7 Structural Analysis of the Predicted pS17 Lid
Conformations. The two lowest energy binding modes of the
phosphorylated pS17 lid (A, C) were obtained using a combination
of multiple docking simulations and structural clustering of low
energy state. The ‘‘|closed’’ form of the bound pS17 lid compared
with p53 binding (PDB ID 1YCR). P53 peptide is shown in grey.
L26, W23 and F19 of p53 are shown in pink and the
phosphorylated pS17 lid is shown in ‘‘ball-and-stick’’ model.
The Connolly surface was generated using the phosphorylated lid.
Structural changes in the MDM2 receptor (residue 26–109) upon
binding of the phosphorylated lid in the two lowest energy clusters
(B, D) were compared with the MDM2 receptor in the complex
with p53 (PDB ID 1YCR ) (shown in magenta). The phosphorylated lid is represented in the ‘‘ball-and-stick’’ model and p53 is
shown in grey color.
(TIF)

Figure S5 Structure-Functional Coupling of the Lid and
Y100 Gating Dynamics. The ensembles of the closed lid
MDM2-pS17 conformations (A) and semi-closed MDM2-S17D
conformations (B) are depicted using representative MDM2
conformations from 10 dominant clusters obtained from MD
simulations. The Y100 residue is shown in ‘‘ball-and-stick’’ model
according to the atom-based coloring scheme. While the closed
conformations of the pS17 lid can induce the ‘‘in’’ conformation of
Y100 (A), the semi-closed S17D conformations induce rotation of
the gate-keeper residue towards the open (‘‘out’’) position (B). A
ribbon-based representation of the MDM2 conformational
ensembles was used. Coloring is according to the B-factors values
(blue-to-red spectrum) reflecting protein nobilities of the MDM2
residues (from more rigid-blue regions to more flexible-red
regions).
(TIF)

Figure S8 Structural Analysis of the Predicted S17D
Conformations. The two lowest energy binding modes of the
phosphorylated S17D lid (A, C) were obtained using a combination of multiple docking simulations and structural clustering of
low energy state. The ‘‘|closed’’ form of the bound S17D lid
compared with p53 binding (PDB ID 1YCR). P53 peptide is
shown in grey. L26, W23 and F19 of p53 are shown in pink and
the phosphorylated pS17 lid is shown in ‘‘ball-and-stick’’ model.
The Connolly surface was generated using the phosphorylated lid.
Structural changes in the MDM2 receptor (residue 26–109) upon
binding of the phosphorylated lid in the two lowest energy clusters
(B, D) were compared with the MDM2 receptor in the complex
with p53 (PDB ID 1YCR ) (shown in magenta). The phosphomimetic lid is represented in the ‘‘ball-and-stick’’ model and p53 is
shown in grey color.
(TIF)

Figure S6 Structural Analysis of the MDM2 Lid Ensembles: Modulation of the MDM2 Ligand Binding. (A)
Structural alignment of the closed lid structure from the
equilibrium ensemble of the phosphorylated pS17 lid (in green
ribbons) and the crystal structure of MDM2 with nutlin (in blue
ribbons) [58]. The position of the lid is indicated with an arrow.
(B) A close-up of the MDM2 binding site shows the overlap and
severe interference between the closed lid (pointed to by an arrow)
and nutlin (in blue sticks). P20 of the closed lid overlaps with the
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96. Grässlin A, Amoreira C, Baldridge KK, Robinson JA (2009) Thermodynamic
and computational studies on the binding of p53-derived peptides and
peptidomimetic inhibitors to HDM2. Chembiochem 10:1360–1368.
97. Kalid O, Ben-Tal N (2009) Study of MDM2 binding to p53-analogues: affinity,
helicity, and applicability to drug design. J Chem Inf Model 49:865–876.
98. Hu G, Wang D, Liu X, Zhang Q (2010) A computational analysis of the
binding model of MDM2 with inhibitors. J Comput Aided Mol Des 24:687–
697.
99. Barakat K, Mane J, Friesen D, Tuszynski J (2010) Ensemble-based virtual
screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
J Mol Graph Model 28:555–568.

PLoS ONE | www.plosone.org

100. Chen J, Wang J, Xu B, Zhu W, Li G (2011) Insight into mechanism of small
molecule inhibitors of the MDM2-p53 interaction: molecular dynamics
simulation and free energy analysis. J Mol Graph Model 30:46–53.
101. Lu SY, Jiang YJ, Zou JW, Wu TX (2011) Molecular modeling and molecular
dynamics simulation studies on pyrrolopyrimidine-based a-helix mimetic as
dual inhibitors of MDM2 and MDMX. J Mol Graph Model 30:167–178.
102. Chen J, Zhang D, Zhang Y, Li G (2012) Computational studies of difference in
binding modes of peptide and non-peptide inhibitors to MDM2/MDMX
based on molecular dynamics simulations. Int J Mol Sci 13:2176–2195.
103. Brown CJ, Dastidar SG, Quah ST, Lim A, Chia B, et al. (2011) C-terminal
substitution of MDM2 interacting peptides modulates binding affinity by
distinctive mechanisms. PLoS One 6:e24122.
104. Shangary S, Wang S (2009) Small-molecule inhibitors of the MDM2-p53
protein-protein interaction to reactivate p53 function: a novel approach for
cancer therapy. Annu Rev Pharmacol Toxicol. 49:223–241.
105. Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM (2010) Molecular
modeling approaches in the discovery of new drugs for anti-cancer therapy: the
investigation of p53-MDM2 interaction and its inhibition by small molecules.
Curr Med Chem 17:3142–3154.
106. Csermely P, Palotai R, Nussinov R (2010) Induced fit, conformational selection
and independent dynamic segments: an extended view of binding events.
Trends Biochem Sci 35:539–546.
107. Changeux JP (2012) Allostery and the Monod-Wyman-Changeux model after
50 years. Annu Rev Biophys 41:103–133.
108. Lange OF, Lakomek NA, Farès C, Schröder GF, Walter KF, et al. (2008)
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